A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

By sjmartinez • December 11, 2024

Perry AS, Hadad N, Chatterjee E, Jimenez-Ramos M, Farber-Eger E, Roshani R, Stolze LK, Betti MJ, Zhao S, Huang S, Martens L, Kendall TJ, Thone T, Amancherla K, Bailin S, Gabriel CL, Koethe J, Carr JJ, Terry JG, Vaitinadin NS, Freedman JE, Tanriverdi K, Alsop E, Van Keuren-Jensen K, Sauld JFK, Mahajan G, Khan SS, Colangelo L, Nayor M, Fisher-Hoch S, McCormick JB, North KE, Below JE, Wells QS, Abel ED, Kalhan R, Scott C, Guilliams M, Gamazon ER, Fallowfield JA, Banovich NE, Das S, Shah R. A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver. Cell Rep Med. 2024 Dec 4:101871. doi: 10.1016/j.xcrm.2024.101871. Epub ahead of print. PMID: 39657669.

Tags: diabetes, Endocrinology, liver-on-a-chip, Metabolic dysfunction-associated steatotic liver disease, non-alcoholic fatty liver disease, proteomics, Publications

Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist Therapy: The Emerging Role of Oral Agents

Wang SY, Stofer R, Wang H, Brent GA, Shi L, Cai Y, Roosan M, Moin T. Bridging Efficacy and Adherence in Glucagon-Like Peptide-1 Receptor Agonist[...]

Impact of a Nurse Practitioner-Led Diabetes Program on Barriers to CGM Use in a Federally Qualified Health Center After Medicaid Expansion

Scarlett LD, Solorzano W, Khoshbin K, Villanueva GP, Mangual KS, Tavares M, Santana C, Escobar B, Borrell J, Brumley B, Moin T, Everett E. Impact[...]

Immune Checkpoint Inhibitor-Associated Uveitis: Predictors and Survival Impact

Chew L, Feng J, Hutchins E, Stein-Merlob AF, Yang EH, Lechner MG, Tsui E. Immune Checkpoint Inhibitor-Associated Uveitis: Predictors and Survival Impact. Ophthalmol Retina. 2025[...]